What's New
Front Page
AFTD Ambassador Emphasizes Need for Better Dementia Care in Podcast
Melissa Fisher, AFTD Ambassador and a senior strategic marketing consultant at Kaiser Permanente Northwest, shared the realities…
AFTD and Passage Bio Discuss Therapeutics Designed for FTD-GRN
AFTD recently spoke with Passage Bio Chief Executive Officer William Chou, M.D., about his colleagues’ work to…
Guest Feature: My Ohana – Reflecting on The Close Bonds We Build on the FTD Journey
FTD symptoms and the stigma attached can make navigating the disease an isolating experience for people diagnosed,…
Schizophrenia Drug Reduces Tau Protein Aggregation in Cell and Mouse Models, Study Finds
Amisulpride, an antipsychotic drug, is capable of reducing aggregation of the tau protein in cell and mouse…
Advancing Hope: AFTD’s Director of Research Engagement Attends Cure VCP Conference
Shana Dodge, PhD, AFTD’s Director of Research Engagement, spoke at the 2023 Cure VCP Connections Conference, held…
Guest Feature: That Picture, That Movie, That Song – Connecting with My Dad Beyond FTD
FTD can distort one’s personality and behavior in unpredictable and upsetting ways, and it can be hard…
AFTD Webinar: Genetic FTD — To Test or Not to Test
The decision to learn one’s own genetic risk for developing FTD is highly personal. An individual’s test…
AFTD and Denali Therapeutics Discuss Takeda Pharmaceuticals Partnership to Develop FTD-Focused Therapeutic
Recently, members of the Denali Therapeutics team provided insights into their work and partnership with Takeda to…
Study Evaluates the Feasibility of ALLFTD’s Mobile App to Collect FTD Diagnostic Data
A study published in the journal Alzheimer’s and Dementia evaluates whether a mobile app developed by the…
STAT Article Explores the Connection Between FTD and Visual Creativity
An article published by STAT explores the connection between the onset of FTD and a spike in…
English 
Spanish (Mexico) 
French 
German 
Swedish 
Portuguese 
Italian 
Dutch 
Danish 
Polish 
Spanish (Spain)